Bufferin Regular Strength Pain Reliefaspirin

According to the FDA label: Uses for the temporary relief of minor aches and pains or as recommended by your doctor. Because of its delayed action, this product will not provide fast relief of headaches or other symptoms needing immediate relief. ask your doctor about other uses for safety coated 81 mg aspirin

499,915 adverse event reports submitted to the FDA (2001–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Bufferin Regular Strength Pain Relief in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Bufferin Regular Strength Pain Relief adverse event reports by reporter sex
SexReports
Male238,982
Female229,260
Unknown1,279

By Age Group

View age group data as a table
Bufferin Regular Strength Pain Relief adverse event reports by reporter age group
Age groupReports
0-174,393
18-347,207
35-4923,774
50-6493,675
65-74103,264
75+104,174

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Bufferin Regular Strength Pain Relief. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Bufferin Regular Strength Pain Relief adverse event reports by reported outcome
OutcomeReports
Other Serious212,860
Hospitalization196,453
Non-Serious140,971
Death45,891
Life-Threatening24,223
Disability14,995

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Bufferin Regular Strength Pain Relief. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Bufferin Regular Strength Pain Relief adverse event reports by year
YearReports
20012
20021
20036
20048,880
200511,013
200612,174
20079,984
200811,361
200917,352
201019,426
201122,910
201224,530
201315,881
201428,381
201528,774
201629,249
201728,071
201828,005
201924,750
202020,712
202126,584
202234,729
202330,383
202429,588
202530,500
2026 (partial)6,669

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Bufferin Regular Strength Pain Relief

In FDA adverse event reports that mention Bufferin Regular Strength Pain Relief, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026